Innovative trial approaches in immune-mediated inflammatory diseases: Current use and future potential

*BMC Rheumatology* 2021; 5:21

Developing a predictive signature for two trial endpoints using the cross-validated risk scores method

*Biostatistics* 2021; DOI: 10.1093/biostatistics/kxaa055

A genome-wide association study identifies SERPINB10, CRLF3, STX7, LAMP3, IFNG-AS1, and KRT80 as risk loci contributing to cutaneous leishmaniasis in Brazil

*Clinical Infectious Diseases* 2021; 72(10):e515-525

Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: A structured summary of a study protocol for a randomised controlled trial

*Trials* 2021; 22:270

Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between IL18RAP expression and treatment response

*Annals of the Rheumatic Disease* 2021; 79(1):1446-1452

Developing and testing high-efficacy patient subgroups within a clinical trial using risk scores

*Statistics in Medicine* 2020; 39(24):3285-3298

A genome-wide association study highlights a regulatory role for IFNG-AS1 contributing to cutaneous leishmaniasis in Brazil

*bioRxiv* 2020; doi:10.1101/2020.01.13.903989

Generalizing rate heterogeneity across sites in statistical phylogenetics

*Statistical Modelling* 2019

Prediction of treatment response in rheumatoid arthritis patients using genome-wide SNP data

*Genetic Epidemiology* 2018; 42(8):754-771

Detecting responses to treatment with fenofibrate in pedigrees

*BMC Genetics* 2018; 19:64